
Onconova Therapeutics, Inc.
NASDAQ:ONTX
Overview | Financials
Company Name | Onconova Therapeutics, Inc. |
Symbol | ONTX |
Currency | USD |
Price | 0.995 |
Market Cap | 20,904,684 |
Dividend Yield | 0% |
52-week-range | 0.551 - 1.45 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Steven M. Fruchtman M.D. |
Website | https://www.onconova.com |
An error occurred while fetching data.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD